By Doug Langa
Executive Vice President North America Operations and President of Novo Nordisk Inc.
100 years ago, 14-year-old Leonard Thompson made history. Leonard was the first human to receive an injection of insulin – his blood sugar levels became near-normal, and for the first time, type 1 diabetes was no longer a death sentence. I stand in awe of the innovation and dedication of the scientists that worked tirelessly to discover this life changing treatment and of the many scientific breakthroughs and innovative solutions that followed. Yet we know that for all insulin has done for patients, there are still 400 million people worldwide living with diabetes that require our collective dedication and hard work to advance treatment options, while working toward a future free of the disease.
Making medicines is our mission at Novo Nordisk but our purpose goes
beyond that. We are committed to driving change for patients in all
the ways that matter, including finding actionable and diverse ways to
advocate for solutions that make it easier for people who need
medicines, to get them.
We encourage anyone in need to go to NovoCare.com to
learn more about the variety of different affordability programs
available from Novo Nordisk. In January 2022, we honor a significant
and miraculous milestone in diabetes, but with all of us doing our
part and continuing that spirit of innovation, it won’t be the